MarketPulse

NSCLC

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

ArriVent to Showcase EGFR Inhibitor and Dual-Target ADC at 2026 AACR Meeting

ArriVent BioPharma presents preclinical data on firmonertinib and ARR-002 ADC at 2026 AACR Annual Meeting, highlighting oncology pipeline progress.
AVBPPhase 3 trialNSCLC
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Junshi Biosciences Wins NMPA Nod for First Domestic Subcutaneous Anti-PD-1 Drug

Junshi Biosciences wins NMPA approval for JS001sc, first domestic subcutaneous anti-PD-1 drug across 12 indications, delivering clinical parity with IV formulation.
ENGNENGNWPhase 3 clinical trialcancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Diamond Equity Research

MAIA Biotech Raises $30M, Eyes 2026 Milestones with Ateganosine Trial Data

MAIA Biotech secures $30M funding and FDA Fast Track designation for ateganosine cancer therapy, with Phase 2 data showing 17.8-month median survival.
MAIAclinical developmentPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

MAIA Biotech Raises $30M in Public Offering to Fund Clinical Trials

MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/share, funding clinical trials and operations.
MAIApublic offeringcommon stock
GlobeNewswire Inc.GlobeNewswire Inc.··Maia Biotechnology, Inc.

MAIA Biotech Taps Capital Markets for Cancer Drug Development Push

MAIA Biotechnology launches underwritten public offering of common stock and pre-funded warrants to fund clinical trials for its lead cancer therapy ateganosine.
MAIAclinical developmentpublic offering
BenzingaBenzinga··Globe Newswire

Candel Therapeutics Plans $100M Stock Offering to Fund Cancer Treatment Pipeline

Candel Therapeutics plans $100M stock offering to fund cancer treatment pipeline development, particularly for prostate and lung cancer therapies.
CADLclinical trialpublic offering